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Introduction Most of data reporting epidemiology of cardiogenic shock
(CS) concern patients with acute myocardial infarction admitted in intensive
care unit of cardiology. However, CS patients managed in critical care unit
(CCU) have often multiorgan failure and seem to have different characteristics
and outcome. To our best knowledge no study reported characteristics and
clinical outcomes of CS patients admitted in CCU.
Aim To report key features, Mortality and Trends in mortality in a large
cohort of patients with CS admitting in 33 French CCUs from 1997 to 2012.
Methods and results We queried the 1997–2012 database of Parisian area
ICUs-the CubRea (Intensive Care Database User Group) database to identify all
hospital stays with a principal or an associated diagnosis of CS (National classifi-
cation of disease R 570). Among 303 314 hospital stays, 17 494 (5.8%) were CS.
The patients were managed in 60% of cases in universitary centers. Mean age was
64.3±17.0. Men accounted for 11047 (63.1%). Mean SAPS II was 62.0±24.3.
Among CS, only 535 (3.06%) were AMI whereas 2685 (15.3%) were cardiac
arrest and 858 (4.9%) were drug intoxications. Mechanical ventilation was
required in 12967 (74.1%) of cases, inotropes in 14640 (83.7%) of cases and renal
support in 3886 (22.2%) of cases. Mean duration of hospital was 19.1 days±24.7.
Intrahospital Mortality was high (46.2%). Predictors of intrahospital death are
reported in Table. Over the 15-year period, mortality decreased (49.8% in 1997-
2000 and 42.7% in 2009-2012, p<0.001) whereas the patients were more critically
ill (SAPS II 58.8±25.4 in 1997-2000 vs 64.2 8±23.6 in 2009-2012, p<0.001).
Conclusion it is the first study reporting the prevalence, determinants and
prognostic factors of CS patients managed in reanimation. The mortality of these
very critically ill patients remains high. However over the 15-year period, even if
these patients are more and more critically ill, early mortality decreased.
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Background Cardiogenic shock is associated with a high mortality rate.
Mechanical circulatory supports have been developed for refractory cardio-
genic shock. The Impella 5.0 device is a rotary microaxial pump mounted on
a catheter across the aortic valve, minimally invasively placed, designed for
short-term circulatory support, and providing left ventricular unloading.
Methods All patients admitted in our cardiac intensive care for acute
refractory cardiogenic shock and treated with Impella 5.0 between January
2010 and January 2015 were included. 
Results 12 patients were enrolled. The causes of cardiogenic shock and
indications for using Impella device were acute myocardial infarction for 6
(50%), decompensated dilated cardiomyopathy for 4 (34%), myocarditis for 1
(8%) and cardiac surgery for 1 (8%). The mean duration of support was 13±8
days. The 30-days and 1-year survival was respectively 75% and 58%. Among
30-days survivors, ventricular function recovered in 5 (56%), 3 (33%) under-
went heart transplant and 1 (11%) underwent implantation of a Heartmate II. 
Conclusion Our outcomes demonstrate that the use of the Impella 5.0
strongly improved survival at 6 months. Myocardial recovery was achieved in
most patients. The Impella also allowed safe implantation of long-term assis-
tance and successful heart transplantation.
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Abstract 0008 – Table
 IMPELLA 5.0
Left ventricular ejection function (%) 21±6
Right ventricular dysfunction n (%) 0 (0)
Cardiac index (L/min/m2) 1.3±0.2
Mean arterial pressure (mmHg) 66±9
Systolic blood pressure (mmHg) 89±13 
Lactates (mmol/L) 6.5±5
Duration of support (days) 14±8
Duration of hospitalisation in intensive care (days) 39±15
30-days survival n (%) 8 (73)
6-months survival n (%) 7 (64)
1-month LEVF (%) 45±9
Myocardial recovery n (%) 4 (63)
Heart transplant (n (%) 3 (11)
LVAD (Heartmate 2) n (%) 1 (9)
Abstratct 0130 – Table
Variables OR 95% CI
Drug intoxication .307 .236 .401
Age (<60 yo) .436 .383 .496
Mechanical circulatory support .681 .378 1.228
Sepsis .715 .637 .802
2009-2012 .998 .885 1.125
SAPS II 1.036 1.033 1.038
Acidosis 1.453 1.264 1.670
Mechanical ventilation 1.718 1.483 1.990
Acute respiratory distress 
syndrome
1.794 1.558 2.066
1997-2000 1.814 1.452 2.267
Hemodialysis 1.820 1.609 2.060
Inotropic use 1.982 1.113 3.530
Disseminated intravascular 
coagulation
2.119 1.591 2.822
Cardiac arrest 4.333 3.840 4.889
